I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

John Martin Biography and Net Worth

Director of Gilead Sciences

John Martin is the former CEO and executive chairman of Gilead Sciences, a pharmaceutical company.

Martin joined Gilead in 1990 as the vice president of research and development before assuming the CEO role in 1996, a position he would hold for 20 years.

He transitioned from his role as president and CEO to chairman and CEO in 2008. After eight years, he became Gilead’s executive chairman in 2016.

While running the pharmaceutical company, Martin expanded its drug portfolio to 24 marketed products and led the Gilead Access Program—an effort to distribute HIV/AIDS, viral hepatitis, and visceral leishmaniasis medicines.

Before joining Gilead, Martin was the director of antiviral chemistry at Bristol-Myers Squibb beginning in 1984.

Martin currently sits on the boards of Sarepta Therapeutics, Kronos Bio, and The Scripps Research Institute. He has previously served on the boards of the International Society for Antiviral Research as president, BayBio as chair, the California Healthcare Institute as chair, and the Biotechnology Industry Organization.

He has also served on the National Institute of Allergy & Infectious Diseases Council, the External Scientific Advisory Board of the University of California School of Global Health, and the board of trustees of both the University of Chicago and Golden Gate University.

The former CEO offered his expertise on the Presidential Advisory Council on HIV/AIDS and the Centers for Disease Control/Health Resources and Services Administration’s Advisory Committee on HIV and STD Prevention and Treatment.

Martin has received numerous awards and accolades, including the American Chemical Society’s Isbell Award, the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research, and the National Academy of Sciences Award for Chemistry in Service to Society. He was also inducted into the National Academy of Engineering in 2008.

Martin earned his bachelor’s degree in chemical engineering at Purdue University, his M.B.A. from Golden Gate University, and his Ph.D. in organic chemistry from the University of Chicago.

What is John C. Martin's net worth?: The estimated net worth of John C. Martin is at least $266.39 million as of December 3rd, 2018. Dr. Martin owns 2,877,762 shares of Gilead Sciences stock worth more than $266,394,428 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Martin may own. Learn More about John C. Martin's net worth.
How do I contact John C. Martin?: The corporate mailing address for Dr. Martin and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on John C. Martin's contact information.
Has John C. Martin been buying or selling shares of Gilead Sciences?: John C. Martin has not been actively trading shares of Gilead Sciences during the last quarter. Most recently, John C. Martin sold 50,000 shares of the business's stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $71.20, for a transaction totalling $3,560,000.00. Following the completion of the sale, the director now directly owns 2,877,762 shares of the company's stock, valued at $204,896,654.40. Learn More on John C. Martin's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 509,823 shares worth more than $46,496,330.96. The most recent insider tranaction occured on December, 16th when CFO Andrew D Dickinson sold 8,500 shares worth more than $781,660.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 12/16/2024.

John C. Martin Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2018	Sell	50,000	$71.20	$3,560,000.00	2,877,762
11/1/2018	Sell	50,000	$69.55	$3,477,500.00	3,067,762
10/1/2018	Sell	50,000	$78.04	$3,902,000.00	3,067,762
9/4/2018	Sell	50,000	$74.16	$3,708,000.00	3,067,762
8/1/2018	Sell	50,000	$77.85	$3,892,500.00	3,067,762
7/2/2018	Sell	50,000	$70.81	$3,540,500.00	3,067,762
6/1/2018	Sell	50,000	$68.13	$3,406,500.00	3,067,762
5/1/2018	Sell	50,000	$72.19	$3,609,500.00	3,067,762
4/2/2018	Sell	50,000	$73.14	$3,657,000.00	3,067,762
3/1/2018	Sell	50,000	$78.65	$3,932,500.00	3,067,762
2/1/2018	Sell	50,000	$83.56	$4,178,000.00	3,046,766
1/2/2018	Sell	50,000	$73.62	$3,681,000.00	3,046,766
12/1/2017	Sell	73,333	$74.98	$5,498,508.34	3,070,099
11/1/2017	Sell	73,333	$75.13	$5,509,508.29	3,070,099
10/2/2017	Sell	73,333	$82.56	$6,054,372.48
9/1/2017	Sell	73,333	$83.11	$6,094,705.63	2,996,766
8/1/2017	Sell	73,333	$75.86	$5,563,041.38	3,199,969
7/3/2017	Sell	73,333	$71.00	$5,206,643.00	3,199,969
4/3/2017	Sell	73,333	$67.18	$4,926,510.94	3,199,969
1/3/2017	Sell	73,337	$73.59	$5,396,869.83	3,204,433
10/3/2016	Sell	100,000	$77.63	$7,763,000.00	3,231,096
9/1/2016	Sell	100,000	$77.48	$7,748,000.00	3,287,810
8/1/2016	Sell	100,000	$80.50	$8,050,000.00	4,119,727
7/1/2016	Sell	100,000	$84.73	$8,473,000.00	4,119,727
5/2/2016	Sell	100,000	$87.82	$8,782,000.00	4,119,727
4/1/2016	Sell	100,000	$93.24	$9,324,000.00	4,119,727
2/1/2016	Sell	100,000	$83.42	$8,342,000.00	3,948,066
1/4/2016	Sell	100,000	$97.68	$9,768,000.00	3,948,066
11/2/2015	Sell	150,000	$109.42	$16,413,000.00	3,948,066
10/1/2015	Sell	150,000	$97.48	$14,622,000.00	3,948,066
9/1/2015	Sell	150,000	$102.73	$15,409,500.00	3,948,066
8/25/2015	Sell	133,213	$105.17	$14,010,011.21	3,948,066
6/1/2015	Sell	150,000	$113.95	$17,092,500.00
4/1/2015	Sell	150,000	$96.74	$14,511,000.00
3/2/2015	Sell	150,000	$103.51	$15,526,500.00
2/2/2015	Sell	150,000	$105.43	$15,814,500.00
1/5/2015	Sell	150,000	$95.12	$14,268,000.00
12/1/2014	Sell	140,633	$100.72	$14,164,555.76
11/3/2014	Sell	140,625	$110.40	$15,525,000.00
10/1/2014	Sell	140,625	$105.91	$14,893,593.75
9/2/2014	Sell	140,625	$108.64	$15,277,500.00
8/1/2014	Sell	140,625	$91.53	$12,871,406.25
7/1/2014	Sell	140,625	$84.84	$11,930,625.00
8/1/2013	Sell	282,242	$61.61	$17,388,929.62
7/1/2013	Sell	282,242	$52.00	$14,676,584.00
6/3/2013	Sell	282,242	$52.84	$14,913,667.28
12/3/2012	Sell	291,000	$75.01	$21,827,910.00

John C. Martin Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $92.57

$90.71

$93.29

50 Day Range

MA: $90.64

$85.05

$97.90

2 Week Range

Now: $92.57

$62.07

$98.90

Volume

22,529,402 shs

Average Volume

7,132,954 shs

Market Capitalization

$115.37 billion

P/E Ratio

1,028.56

Dividend Yield

3.40%

Beta

0.18

I was wrong. Dead wrong.

From Porter & Company | Ad